The MonarchE trial: improving the clinical outcome in HR+/HER2- early breast cancer: recent results and next steps

被引：4
|
作者：
Bertucci, Francois [1 ,2 ,3 ]
Finetti, Pascal [1 ]
Mamessier, Emilie [1 ]
De Nonneville, Alexandre [1 ,2 ]
机构：
[1] Aix Marseille Univ, Paoli Calmettes Inst, Canc Res Ctr Marseille, Lab Predict Oncol,INSERM,CNRS,UMR 1068,UMR 725,Tea, Marseille, France
[2] Paoli Calmettes Inst, Dept Med Oncol, Marseille, France
[3] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguer, F-13009 Marseille, France
来源：
CANCER COMMUNICATIONS | 2023年 / 43卷 / 08期
关键词：
PALBOCICLIB;
D O I：
10.1002/cac2.12466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 942
页数：5
相关论文
共 50 条
  • [41] Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
    Canino, Fabio
    Moscetti, Luca
    Borghi, Vanni
    Dominici, Massimo
    Piacentini, Federico
    BREAST CANCER MANAGEMENT, 2021, 10 (04)
  • [42] Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: A chart review study in the US
    Xie J.
    Hao Y.
    Li N.
    Lin P.L.
    Ohashi E.
    Koo V.
    Wu E.Q.
    Experimental Hematology & Oncology, 4 (1)
  • [43] Ribociclib effective in HR+, HER2– breast cancer
    Sidaway P.
    Nature Reviews Clinical Oncology, 2018, 15 (9) : 532 - 532
  • [44] Tumour stroma characterization for the clinical stratification of HR+/HER2-breast cancer
    Scatena, C.
    Fanelli, G. N.
    Belcastro, E.
    Di Cocco, F.
    Fontana, A.
    Szumera-Cieckiewicz, A.
    Loda, M.
    Naccarato, A. G.
    VIRCHOWS ARCHIV, 2024, 485 : S5 - S5
  • [45] Long-term Patient-reported Outcomes from monarchE: Abemaciclib plus Endocrine Therapy for Adjuvant HR+, HER2-, Node-positive, High-risk, Early Breast Cancer
    Harbeck, Nadia
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    Mcintyre, Kristi
    Wei, Ran
    Antonio, Belen San
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Tolaney, Sara M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 31 - 31
  • [46] Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, S.
    Blancas, I.
    Im, Y. -H.
    Rastogi, P.
    Brown, J.
    Shahir, A.
    Zimmermann, A.
    Boyle, F.
    BREAST, 2021, 56 : S20 - S21
  • [47] Biomarker analysis in HR+, HER2-, locally advanced, or metastatic breast cancer patients treated with buparlisib: results from BELLE-3
    Solovieff, Nadia
    Wang, Ying A.
    Sankaran, Banu
    Scheuer, Nicolas
    El-Hashimy, Mona
    Weber, Denis
    Sellami, Dalila
    Di Leo, Angelo
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [48] Development of a Prognostic Factor Index Among Women With HR+/HER2- Metastatic Breast Cancer in a Community Oncology Setting
    Vidal, Gregory A.
    Carter, Gebra Cuyun
    Gilligan, Adrienne M.
    Saverno, Kim
    Zhu, Yajun Emily
    Price, Gregory L.
    DeLuca, Angelo
    Smyth, Emily Nash
    Rybowski, Sarah
    Huang, Yu-Jing
    Schwartzberg, Lee S.
    CLINICAL BREAST CANCER, 2021, 21 (04) : 317 - +
  • [49] Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients
    Li, Shuai
    Chen, Xiaosong
    Shen, Kunwei
    FRONTIERS IN SURGERY, 2022, 9
  • [50] Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, Sara M.
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    McIntyre, Kristi
    Wei, Ran
    Munoz, Maria
    San Antonio, Belen
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Harbeck, Nadia
    EUROPEAN JOURNAL OF CANCER, 2024, 199
12345